Sharks give a handle to potent anti-tumor multiparatopic antibodies inducing membrane depletion of PD-L1

被引:0
|
作者
Wozniak-Knopp, Gordana [1 ,2 ]
Natale, Veronica [1 ,2 ]
机构
[1] BOKU Univ, Inst Mol Biotechnol, Dept Biotechnol, Vienna, Austria
[2] Acib GmbH Austrian Ctr Ind Biotechnol, Graz, Austria
关键词
D O I
10.1016/j.chembiol.2024.04.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite the immense clinical success of the antibody therapeutics that neutralize programmed death receptor ligand 1 (PD -L1) and thus resurrect T cell antitumor activity, the patient response rates remain low. In this issue of Cell Chemical Biology , Ludwig et al. 1 reveal novel topologies of multiparatopic antibodies that mediate potent PD -L1 downregulation.
引用
收藏
页码:833 / 834
页数:2
相关论文
共 50 条
  • [31] Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer
    Luo, Lianxiang
    Wu, Tong
    Ji, Miaorong
    Xiang, Jing
    Zou, Youwen
    Liao, Yinglin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 133
  • [32] Energy status dictates PD-L1 protein abundance and anti-tumor to enable blockade
    Dai, Xiaoming
    Bu, Xia
    Gao, Yan
    Guo, Jianping
    Hu, Jia
    Jiang, Cong
    Zhang, Zhao
    Xu, Kexin
    Duan, Jinzhi
    He, Shaohui
    Zhang, Jinfang
    Wan, Lixin
    Liu, Tianjie
    Zhou, Xiaobo
    Hung, Mien-Chie
    Freeman, Gordon J.
    Wei, Wenyi
    MOLECULAR CELL, 2021, 81 (11) : 2317 - +
  • [33] BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
    Zhu, Hengrui
    Bengsch, Fee
    Svoronos, Nikolaos
    Rutkowski, Melanie R.
    Bitler, Benjamin G.
    Allegrezza, Michael J.
    Yokoyama, Yuhki
    Kossenkov, Andrew V.
    Bradner, James E.
    Conejo-Garcia, Jose R.
    Zhang, Rugang
    CELL REPORTS, 2016, 16 (11): : 2829 - 2837
  • [34] A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
    Cui, Xiaopei
    Jia, Huifeng
    Xin, Hong
    Zhang, Lei
    Chen, Shi
    Xia, Simin
    Li, Xue
    Xu, Wei
    Chen, Xiaofang
    Feng, Yujie
    Wei, Xiaoyue
    Yu, Haijia
    Wang, Yanting
    Zhan, Yifan
    Zhu, Xiangyang
    Zhang, Xuemei
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [35] Targeting Glutamine Metabolism and PD-L1: A Novel Anti-tumor Pas de Deux
    Matias, Maria I.
    Dardalhon, Valerie
    Taylor, Naomi
    MOLECULAR CELL, 2020, 80 (04) : 555 - 557
  • [36] MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity
    Xiong, Wei
    Deng, Huanghao
    Huang, Changkun
    Zen, Chong
    Jian, Chengzhu
    Ye, Kun
    Zhong, Zhaohui
    Zhao, Xiaokun
    Zhu, Liang
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2019, 1865 (02): : 454 - 463
  • [37] Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade
    Jiang, Yuying
    Yang, Yongbing
    Hu, Yingchao
    Yang, Rui
    Huang, Jiajia
    Liu, Yi
    Wu, Yuqing
    Li, Sheng
    Ma, Chunmei
    Humphries, Fiachra
    Wang, Bingwei
    Wang, Xi
    Hu, Zhibin
    Yang, Shuo
    CELL REPORTS, 2022, 41 (04):
  • [38] Multispecific antibodies targeting CD38 and PD-L1 show potent tumor cytotoxicity
    van Schooten, Wim
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Combination of NK Cells and anti-PD-L1 Ab with ADCC enhances the anti-tumor effects in PD-L1 high cancer cells
    Park, Ji-Eun
    Keam, Bhumsuk
    Park, Ha-ram
    Kim, Soyeon
    Ock, Chan-Young
    Kim, Miso
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [40] CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.
    Li, Chris
    Vilalta, Marta
    Ertl, Linda S.
    Wang, Yu
    Zeng, Yibin
    Fan, Pingchen
    Lange, Christopher
    McMurtrie, Darren
    Yang, Ju
    Lui, Rebecca
    Scamp, Ryan
    Chhina, Vicky
    Kumamoto, Alice
    Ong, Ryan
    Dang, Ton
    Easterday, Ashton
    Zhao, Niky
    Liu, Shirley
    Singh, Rajinder
    Charo, Israel
    Sullivan, Kathleen
    Schall, Thomas J.
    Zhang, Penglie
    CANCER RESEARCH, 2021, 81 (13)